Fatores de prognóstico favorável em pacientes com glioblastoma

Vital Pedro dos Santos Junior, Thailane Márie Feitosa Chaves, Mario Teruo Yanagiura, Aurigena Antunes de Araújo, Ródio Luís Brandão Câmara

Resumo


O objetivo deste trabalho foi identificar, os fatores que contribuem para o prognóstico favorável em pacientes com glioblastoma, de modo a fornecer dados que possam auxiliar no manejo desses pacientes. Trata-se de uma revisão sistemática da literatura científica, dos últimos nove anos, nas bases de dados PubMed e Web of Science, utilizando os descritores “glioblastoma and prognostic factors”. Aplicados os critérios de inclusão e exclusão, foram selecionados 23 artigos, os quais foram utilizados no desenvolvimento do trabalho. As variáveis mais estudadas foram idade, Karnofsky Perfomance Scale pré-operatório tratamento cirúrgico, terapia adjuvante, extensão da doença, alterações genéticas e moleculares. Fatores clínicos, genéticos, aspectos do tumor e tratamento mostraram ser importantes para o melhor prognóstico desses pacientes. Dentre esses, apresentam maiores chances de melhoria os mais jovens, com bom estado de performance inicial Karnofsky Performance Scale pré-operatório, tumor único, unilateral, tratado com cirurgia de ressecção extensa e radioterapia e quimioterapia adjuvantes (inclusive se for idoso), e panorama genético molecular favorável (aumento da expressão de N-myc downstream-regulated gene-1 em glioma em comparação com os tecidos normais do cérebro; hipermetilação do gene O6-metilguanina-metiltransferase; mutação Isocitrate Dehydrogenase-1 e ausência de expressão de Single-Stranded Deoxyribonucleic Acid-Binding Protein-2.

Palavras-chave: Glioblastoma. Literatura de revisão por assunto. Prognóstico.


Palavras-chave


Glioblastoma. Literatura de revisão por assunto. Prognóstico.

Texto completo:

PDF

Referências


Amoureux MC, Coulibaly B, Chinot O, Loundou A,

Metellus P, Rougon G, et al. Polysialic Acid Neural

Cell Adhesion Molecule (PSA-NCAM) is an adverse

prognosis factor in glioblastoma, and regulates olig2

expression in glioma cell lines. BMC Cancer. 2010;

(91):1-12.

Saghafian-Hedengren S, Sverremark-Ekstrom E, Linde

A, Lilja G, Nilsson C. Early-life EBV infection protects

against persistent IgE sensitization. J Allergy Clin

Immunol. 2010; 125(2):433-8.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger

PC, Jouvet A, et al. The 2007 WHO classification of

tumours of the central nervous system. Acta

Neuropathol. 2007; 114(5):547.

Burger PC, Green SB. Patient age, histologic features,

and length of survival in patients with glioblastoma

multiforme. Cancer. 1987; 59(9):1617-25.

Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos

MC. Survival of patients with glioblastoma multiforme

has not improved between 1993 and 2004: Analysis

of 625 cases. Br J Neurosurg. 2007; 21(5):496-500.

Grant R. Overview: Brain tumour diagnosis and management/

Royal College of physicians guidelines. J

Neurol Neurosur Psychiatry. 2004; 75(Suppl 2):18-23.

Lucena RCG, Mello RJV, Lessa Jr. JR, Cavalcante GM,

Ribeiro M. Correlação clínico-topográfica em

glioblastomas multiformes nas síndromes motoras:

significados fisiopatológicos. Arq Neuropsiquiatr.

; 64(2-B):441-5.

Kleihues P, Ohgaki H. Primary and secondary

glioblastomas: From concept to clinical diagnosis.

Neuro Oncol. 1999; 1(1):44-51.

Prados MD, Berger MS, Wilson CB. Primary central

nervous system tumors: Advances in knowledge and

treatment. CA Cancer J Clin. 1998; 48(6):331-60.

Lopez-Gonzalez MA, Sotelo J. Brain tumors in Mexico:

Characteristics and prognosis of glioblastoma. Surg

Neurol. 2000; 53(2):157-62.

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch

T, Simon M, et al. Long-term survival with glioblastoma

multiforme. Brain. 2007; 130(Pt 10):2596-606.

Smith JS, Jenkins RB. Genetic alterations in adult

diffuse glioma: Occurrence, significance, and

prognostic implications. Front Biosc. 2000; 5:D213-31.

Evers P, Lee PP, DeMarco J, Agazaryan N, Sayre JW,

Selch M, et al. Irradiation of the potential cancer stem

cell niches in the adult brain improves progressionfree

survival of patients with malignant glioma. BMC

Cancer. 2010; 10(384):1-12.

Badaoui N, Meyronet D, Cartalat-Carel S, Guyotat J,

Jouanneau E, d’Hombres A, et al. Patterns of care and

survival of glioblastoma patients: A comparative study

between 2004 and 2008 in Lyon, France. Rev Neurol.

; 170(3):222-7.

Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone

MG, Caldiroli D, et al. Prognostic factors for survival in

consecutive patients with newly diagnosed primary

glioblastoma. Neuro Oncol. 2008; 10(1):79-87.

Helseth R, Helseth E, Johannesen TB, Langberg CW,

Lote K, Ronning P, et al. Overall survival, prognostic

factors, and repeated surgery in a consecutive series

of 516 patients with glioblastoma multiforme. Acta

Neurol Scand. 2010; 122(3):159-67.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach

JP, Schramm J, et al. Molecular predictors of

progression-free and overall survival in patients with

newly diagnosed glioblastoma: A prospective

translational study of the German Glioma Network. J

Clin Oncol. 2009; 27(34):5743-50.

Wang SJ, Zhao Y, Ruan ZC, Chen HY, Fan WW, Chen

JX, et al. Association between EGF +61 G/A and

glioma risk in a Chinese population. BMC Cancer.

; 10(221):1-13.

Henriksson R, Asklund T, Poulsen HS. Impact of

therapy on quality of life, neurocognitive function

and their correlates in glioblastoma multiforme: A

review. Neuro Oncol. 2011; 104(3):639-46.

Ahluwalia MS. American Society of Clinical Oncology

CNS tumors update. Expert Rev Anticancer Ther.

; 11(10):1495-7.

Lutterbach J, Bartelt S, Momm F, Becker G, Frommhold

H, Ostertag C. Is older age associated with a worse

prognosis due to different patterns of care? A longterm

study of 1346 patients with glioblastomas or

brain metastases. Cancer. 2005; 103(6):1234-44.

Iwamoto FM, Cooper A, Reiner AS, Nayak L, Abrey LE.

Glioblastoma in the Elderly: The Memorial Sloan-

Kettering Cancer Center Experience (1997-2007).

Neurology. 2009; 72(11):A110-A1.

Oszvald A, Guresir E, Setzer M, Vatter H, Senft C, Seifert

V, et al. Glioblastoma therapy in the elderly and the

importance of the extent of resection regardless of

age. J Neurosurg. 2012; 116(2):357-64.

Sun B, Chu D, Li W, Chu X, Li Y, Wei D, et al. Decreased

expression of NDRG1 in glioma is related to tumor

progression and survival of patients. Neuro Oncol.

; 94(2):213-9.

Linnebank M, Semmler A, Moskau S, Smulders Y, Blom

H, Simon M. The Methylenetetrahydrofolate

Reductase (MTHFR) variant c.677C>T (A222V)

influences overall survival of patients with

glioblastoma multiforme. Neuro Oncol. 2008;

(4):548-52.

Simon M, Ludwig M, Fimmers R, Mahlberg R, Muller-

Erkwoh A, Koster G, et al. Variant of the CHEK2 gene

as a prognostic marker in glioblastoma multiforme.

Neurosurgery. 2006; 59(5):1078-85.

Vauleon E, Auger N, Benouaich-Amiel A, Laigle-

Donadey F, Kaloshi G, Lejeune J, et al. The 61 A/G EGF

polymorphism is functional but is neither a prognostic

marker nor a risk factor for glioblastoma. Cancer Genet

Cytogenet. 2007; 172(1):33-7.

Carson KA, Grossman SA, Fisher JD, Shaw EG.

Prognostic factors for survival in adult patients with

recurrent glioma enrolled onto the new approaches

to brain tumor therapy CNS consortium phase I and II

clinical trials. J Clin Oncol. 2007; 25(18):2601-6.

Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia

GL, Blakeley J, et al. Multiple resections for patients

with glioblastoma: Prolonging survival Clinical article.

J Neurosurg. 2013; 118(4):812-20.

Gutenberg A, Bock HC, Reifenberger G, Bruck W,

Giese A. Toxicity and survival in primary glioblastoma

patients treated with concomitant plus adjuvant

temozolomide versus adjuvant temozolomide:

Results of a single-institution, retrospective, matchedpair

analysis. Acta Neurochir. 2013; 155(3):429-35.

Okumus NO, Gursel B, Meydan D, Ozdemir O, Odabas

E, Gonullu G. Prognostic significance of concomitant

radiotherapy in newly diagnosed glioblastoma

multiforme: A multivariate analysis of 116 patients.

Ann Saudi Med. 2012; 32(3):250-5.

Paccapelo A, Lolli I, Fabrini MG, Silvano G, Detti B,

Perrone F, et al. A retrospective pooled analysis of

response patterns and risk factors in recurrent

malignant glioma patients receiving a nitrosoureabased

chemotherapy. J Transl Med. 2012; 10(90):1-7.

Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone

MG, Caldiroli D, et al. Prognostic factors for survival in

consecutive patients with newly diagnosed primary

glioblastoma. Neuro Oncol. 2008; 10(1):79-87.

Xiao YY, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka

JS, et al. SSBP2 variants are associated with survival in

glioblastoma patients. Clin Cancer Res. 2012;

(11):3154-62.

Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, et al.

Correlation of IDH1 mutation with clinicopathologic

factors and prognosis in primary glioblastoma: A

report of 118 patients from China. Plos One. 2012;

(1):e30339.

Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL.

Epidemiology of brain tumors. Neurol Clin. 2007;

(4):867-90.

Simon M, Ludwig M, Fimmers R, Mahlberg R, Müller-

-Erkwoh A, Köster G, et al. Variant of the CHEK2

gene as a prognostic marker in glioblastoma

multiforme - Comments. Neurosurgery. 2006;

(5):1078-85.

Sanchez-Herrera F, Castro-Sierra E, Gordillo-

-Dominguez LF, Vaca-Ruiz MA, Santana-Montero B,

Perezpena-Diazconti M, et al. Glioblastoma

multiforme in children: Experience at Hospital Infantil

de Mexico Federico Gomez. Childs Nerv Syst. 2009;

(5):551-7.

Wiencke JK, Aldape K, McMillan A, Wiemels J,

Moghadassi M, Miike R, et al. Molecular features of

adult glioma associated with patient race/ethnicity,

age, and a polymorphism in O-6-methylguanine-

DNA-methyltransferase. Cancer Epidemsive Biomar.

; 14(7):1774-83.

Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M,

Ushio Y. Correlation between promoter

hypermethylation of the O6-methylguaninedeoxyribonucleic

acid methyltransferase gene and

prognosis in patients with high-grade astrocytic

tumors treated with surgery, radiotherapy, and 1-(4-

amino-2-methyl-5-pyrimidinyl) methyl-3-(2-

chloroethyl)-3-nitrosourea-basedchemotherapy.

Neurosurgery. 2004; 54(2):349-57.

Lachat P, Shaw P, Gebhard S, van Belzen N, Chaubert

P, Bosman FT. Expression of NDRG1, a differentiationrelated

gene, in human tissues. Histochem Cell Biol.

; 118(5):399-408.




DOI: https://doi.org/10.24220/2318-0897v23n1a2414

Apontamentos

  • Não há apontamentos.


Revista de Ciências Médicas

ISSNe 2318-0897 (eletrônico)
ISSN 1415-5796 (impresso)

Este site é melhor visualizado utilizando navegador gratuito Firefox.